Illumina to divest cancer test maker Grail after antitrust battles

[ad_1] Rafael Henrique | Lightrocket | Getty Images Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after the companies battled both U.S. and…

Illumina to Divest Itself of Cancer-Test Maker Grail

[ad_1] Updated Dec. 17, 2023 8:16 pm ET Gene-sequencing company Illumina said Sunday it will divest itself of cancer blood test maker Grail, following Illumina’s loss in its legal battle…

Illumina Links Grail Divestiture to Losing European Or U.S. Appeals

[ad_1] by Alex Philippidis Illumina responded Friday to the European Commission (EC)’s order to divest itself of cancer blood test developer Grail by saying it will comply should it lose…

Illumina names new CEO months after Icahn proxy fight over Grail deal

[ad_1] A building on the campus at the world headquarters of Illumina is shown in San Diego, California, Sept. 1, 2021. Mike Blake | Reuters Illumina‘s board on Tuesday named…

‘Remarkable’ AI opportunity whets News Corp’s appetite for elusive holy grail — a lucrative new revenue stream

[ad_1] Profits at Rupert Murdoch’s News Corp might have dropped 75 per cent in the year to the end of June — to $187 million (€170 million) — but dollar…

SEC investigating Illumina over acquisition of cancer test developer Grail

[ad_1] A building on the campus at the world headquarters of Illumina is shown in San Diego, California, Sept. 1, 2021. Mike Blake | Reuters The U.S. Securities and Exchange…

Illumina acquisition of Grail wins support from GOP lawmakers, state AGs as FTC tries to block it

[ad_1] Rafael Henrique | Lightrocket | Getty Images Republican lawmakers, state attorneys general and several advocacy groups have voiced their support for Illumina’s acquisition of cancer-test developer Grail while the…

Tech Billionaires Bet on Fusion as Holy Grail for Business

[ad_1] Jeff Bezos, Marc Benioff and Peter Thiel are some of the titans chasing the almost limitless energy source. [ad_2] Source link

FTC Rejects Illumina’s $7 Billion Deal for Cancer-Test Developer Grail

[ad_1] The agency said the combination would hurt competition for cancer-detection tests while raising prices. [ad_2] Source link

Illumina Should Heed Carl Icahn, Give Up on Grail

[ad_1] Management should seek a settlement with the activist that paves the way for a speedier Grail exit [ad_2] Source link